[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ukrainian Society of Clinical Oncology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":155},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,56,82,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100617050","hyperthermic-intraperitoneal-chemoperfusion-hipec-in-gastric-cancer-100617050",false,"NCT07313579","Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer","Observational Prospective Cohort Study on Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer","G-PEC","Inclusion Criteria:\n\n1. Age 18-80\n2. Hystologicaly proven gastric adenocarcinoma\n3. ECOG status 0-1\n4. Written consent to participate in the study\n5. Medically and technically operable gastric tumor\n6. Only T4a or T4b tumours with any peritoneal cytology status\n7. Cytologically positive peritoneal washings (cyt+) with any T and N criteria\n8. Adequate haemopoetic, renal and hepatic function (Hb \\> 120, PLT \\> 150\\*10\\^9\u002Fl, ALT \\\u003C 60, AST \\\u003C40, total bilirubin \\\u003C 21 µmol\u002Fl, Creatinine clearance (male - 90-140, female - 80-130 ml\u002Fmin)\n\nExclusion Criteria:\n\n1. Pregnancy\u002Fbreastfeeding\n2. ECOG status 2-4\n3. Concomitant malignancy\n4. Mitomycin and\u002For Cisplatin hypersensitivity\n5. Uncontrollable chronic diseases\n6. Patients with coexisting malignancy other than basal cell carcinoma of the skin within the last five years.\n7. Presence of metastases other than regional or peritoneal (such as liver, lungs, bone, brain, distant lymph nodes)\n8. History of allergic reactions associated with cisplatin and Mitomycin C\n9. Patients with psychiatric illness\u002Fsocial situations with impaired compliance\n10. •Refusal to participate","ALL","18 Years","80 Years",{"count":21,"type":22},200,"ESTIMATED","OBSERVATIONAL","The study investigates the outcomes of hyperthermic intraperitoneal chemoperfusion (HIPEC) in combination with curative-intent gastrectomy in resectable locally-advanced and limited-metastatic (low peritoneal cancer index) gastric cancer.",[26,27,28,29],"Gastric Cancer (GC)","HIPEC","Peritoneal Metastases From Gastric Cancer","Hyperthermic Intraperitoneal Chemoperfusion",[31,27,29,32,33,34,35,36,37,38,39,40,41,42],"Gastric cancer","FLOT","Lymphadenectomy","Gastrointestinal Neoplasms","Digestive System Neoplasms","Gastrointestinal Diseases","Stomach Diseases","Stomach Neoplasms","Chemotherapy, Adjuvant","Combined Modality Therapy","Drug Therapy","Surgical Procedures","RECRUITING","2026-01-10",{"date":46,"type":47},"2026-01-13","ACTUAL",{"date":49,"type":47},"2025-12-01",{"date":51,"type":22},"2035-12-01",{"name":53,"class":54},"Ukrainian Society of Clinical Oncology","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":64,"enrollmentInfo":65,"targetDuration":67,"studyType":23,"phases":4,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":81,"locationsCount":55},"100615640","impact-of-endo-vac-therapy-for-esophago-jejunal-anastomotic-leak-100615640","NCT07295236","Impact of Endo-vac Therapy for Esophago-jejunal Anastomotic Leak","Prospective Observational Study on Endo-vac Therapy for Esophago-jejunal Anastomotic Leak","ENDO-VAL","Inclusion Criteria:\n\n* patients who developed esophago-jejunal anastomotic leak less than 50% of circumference of anastomosis\n* patients who developed esophago-jejunal anastomotic leak and remained stable at the moment of diagnosis with no indications for diversion surgery\n\nExclusion Criteria:\n\n* unstable patients who developed esophago-jejunal anastomotic leak\n* patients who developed esophago-jejunal anastomotic leak more than 50% or anastomotic circumference\n* patients who rejected endoscopic vacuum therapy","90 Years",{"count":66,"type":22},100,"5 Years","The goal of this observational study is to assess the impact of endoscopic vacuum therapy in patients who underwent total gastrectomy due to gastric cancer and developed esophago-jejunal anastomotic leakage. The main outcomes to be investigated are the following:\n\nPrimary endpoint: mortality rate Secondary endpoints: morbidity rate, time from AL diagnosis to discharge, patients satisfactory rate.",[70],"Esophagojejunal Anastomotic Leak",[72,73,74,75],"gastric cancer","esophagojejunal anastomotic leak","total gastrectomy","Endoscopic vacuum therapy","2025-12-21",{"date":78,"type":47},"2025-12-29",{"date":49,"type":47},{"date":51,"type":22},{"name":53,"class":54},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":93,"briefSummary":96,"conditions":97,"keywords":114,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100518299","phase-2-total-neoadjuvant-flot-chemotherapy-in-locally-advanced-gastric-and-gastroesophageal-junction-cancer-100518299","NCT06028737","Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer","Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin, and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Multi-center, Open-label Trial, Phase 2\u002F3","OCTASUR","Inclusion Criteria:\n\n* Tumor spread according to TNM: ≥cT3 and\u002For ≥cN0 and M0 (except of invasion of the common hepatic artery, celiac trunk, proximal part of the splenic artery, aorta, head of the pancreas);\n* Performance status by Eastern Cooperative Oncology Group (ECOG): 0 - 1;\n* Histologically confirmed gastric adenocarcinoma or gastroesophageal junction (Siewert type 2\u002F3) adenocarcinoma.\n* Differentiation grade: G0 - G4;\n* Tumor localization: cardio-esophageal junction (Siewert 2, 3), cardiac part of the stomach, body of the stomach, antral part of the stomach, pyloric part of the stomach;\n* Tumor extension: esophagus, diaphragm, liver, body and tail of the pancreas, anterior abdominal wall, small and large intestine, distal part of the splenic artery, spleen;\n* Patient agrees to participate in this biomedical study.\n\nExclusion Criteria:\n\n* Presence of another oncological disease at a different site if less than 5 years have passed since radical treatment.\n* Comorbidities or patient conditions that preclude the administration of chemotherapy.",{"count":91,"type":22},150,"INTERVENTIONAL",[94,95],"PHASE2","PHASE3","The main goal of this study is to investigate the proportion of participants with locally advanced gastric and gastroesophageal adenocarcinoma without previous treatment during the last 5 years who can tolerate all planned cycles of chemotherapy and radical surgical treatment who will be prospectively randomized into two groups to undergo one of two chemotherapy regimens, followed by surgery:\n\n1. 8 cycles of Total Neoadjuvant ChemoTherapy (TNT) with 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, and Docetaxel (FLOT) followed by surgery.\n2. 4 cycles of Neoadjuvant FLOT chemotherapy scheme preoperatively and 4 adjuvant FLOT cycles postoperatively.",[98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113],"Gastric Cancer","Stomach Cancer","GastroEsophageal Cancer","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Advanced Gastric Adenocarcinoma","Gastric Neoplasm","Stomach Neoplasm","Gastrointestinal Cancer","Advanced Gastroesophageal Junction Adenocarcinoma","Advanced Gastric Carcinoma","Chemotherapy","Gastrectomy","Gastrectomy for Gastric Cancer","Gastric Resection","Gastric (Cardia, Body) Cancer",[115,32,116,110,117,118,119,120,31],"Total neoadjuvant chemotherapy","Fluoruracil","Perioperative chemotherapy","Docetaxel","Leucovorin","Gastric resection","2025-04-30",{"date":123,"type":47},"2025-05-06",{"date":125,"type":47},"2025-03-25",{"date":127,"type":22},"2032-12-31",{"name":53,"class":54},2,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":92,"phases":140,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":129},"100574151","phase-3-investigation-of-impact-of-indocyanine-green-on-volume-of-lymphadenectomy-in-resectable-gastric-cancer-100574151","NCT06755554","Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer","Investigation of Effect of Indocyanine Green on Volume of Lymph Node Dissection in Surgical Treatment of Gastric Cancer","ICGastr","Inclusion Criteria:\n\n* Tumor spread: cT2-4a cN0-3,\n* cM0;\n* Age: 18 - 80;\n* Gender: men and women;\n* ECOG: 0 - 1;\n* Histologic type of tumor: Adenocarcinoma of any subtype;\n* Degree of differentiation: G1 - G4;\n* Tumor localization: cardiac region, stomach floor, stomach body, antrum, pylorus, and pyloric region of the stomach;\n* Tumor spread: absence of tumor invasion into adjacent structures;\n* No history of cancer in the last 5 years;\n* No previous chemotherapy, surgery or radiation treatment for another cancer (except for neoadjuvant chemotherapy for gastric cancer);\n* Absence of severe comorbidity restricting laparoscopic approach.\n\nExclusion Criteria:\n\n* M1 (distant metastases);\n* ECOG 2 - 4;\n* Age over 80 and under 18;\n* Presence of severe comorbidities, ASA\\> 3;\n* Patient refusal to participate in the study.",{"count":139,"type":22},105,[95],"The study aims to evaluate the safety and benefits of using indocyanine green in lymph node dissection for gastric cancer surgery. The primary endpoint is the average number of lymph nodes removed. Secondary study points are the average number of ICG-positive lymph nodes; the average number of metastatic ICG-positive lymph nodes; the number of postoperative complications and complications associated with the administration of ICG.\n\nPatients who meet the inclusion criteria for this study will be enrolled in the study after reviewing and signing an informed consent form.\n\nAll patients will be included in one group and will receive surgical treatment in the amount of total or subtotal gastrectomy with lymphadenectomy D1, D1+, D2 or D2+.\n\nICG is injected by the patient by endoscopic submucosal injection into 4 points around the tumor 24-12 hours before the start of the surgical intervention.\n\nAssessment of the number of fluorescent lymph nodes will be performed intraoperatively with their subsequent removal and mapping. The incidence of postoperative complications will be assessed by Clavien-Dindo.",[143,144,98,111],"Gastric Cancer Stage II","Gastric Cancer Stage III",[146,72,147],"indocyanine green","gastrectomy",{"date":149,"type":47},"2025-03-30",{"date":151,"type":47},"2025-01-01",{"date":153,"type":22},"2026-02-01",{"name":53,"class":54},""]